




COMPANY PRESENTATION

WARSAW // 2023

Evolution from branded generics to innovations






Company highlights




- Founded in 2002
- Unique hybrid model combining positive cash flows and integrated pharma business experience with a diversified pipeline of highly innovative programs
- Disciplined new program selection, focusing on un-met medical needs



- Driven by the best people 500+ employees
- Highly experienced management team
- Founder-led teams with scientific backgrounds: 200+ scientists



- Broad pipeline of 5 clinical stage assets and multiple identified leads targeting large market opportunities in neuropsychiatry, oncology, metabolism & inflammation
- Potential blockbusters with wholly owned IP
- Advanced early-stage pipeline: 12 innovative programs in pre-clinical



- Footprint in >30 countries
- Diversified enabling internal resources portfolio leading to the improved probability of success
- Collaborating at center of the biotech ecosystem

Led by a seasoned management team



Maciej Wieczorek, PhD

CEO, President of the Management Board

- Founder and President of the Management Board of Celon Pharma
- PhD in Medical Biology at the Medical University of Lodz (PL)
- Scholarship of New University of Lisbon in Portugal, while also completed MBA at the Warsaw School of Economics and the University of Minnesota
- Inventor or co-inventor of several patent applications for classic chemical and biotechnological drugs, as well as the driving force for the launch of several of the best-selling drugs in Poland



Bartosz Szalek

CFO

- Experienced manager in building the value of fast-growing international enterprises, who has been cooperating with private equity funds for over 15 years, supervising the finances of portfolio companies.
- He worked in the banking sector in corporate banking at Bank Pekao SA and Deutsche Bank SA. He gained experience in financial positions in international corporations SAP Polska and Żywiec Zdrój SA (Danone Group);
- Board member / CFO in companies such as ThyssenKrupp Stainless Polska, GTX Hanex, Novago and Krosno Glass SA, among others.




HYBRID COMPANY - PART I

INNOVATIVE
BUSINESS




Therapeutic areas





R&D centre:



More than
46.000 m²



350+
scientists

NEW:

Recombinant biotech: mammalian & microbiomes
Modern analytics



Diversified platforms drives strong pipeline




* Idiopathic pulmonary delay [IPF] / Arterial pneumonia [PAH] / Rheumatoid arthritis [RA] / Psoriasis

** Psoriatic arthritis / Giant cell arteritis / Steroid resistant asthma


■ Recombinant proteins
 ■ Small molecules
 ■ mRNA

News flow & key milestones 2023



-  Metabolic diseases
-  Oncology
-  Neuropsychiatry
-  Inflammatory diseases

Partnering strategy 2023/2024



-  Metabolic diseases
-  Oncology
-  Neuropsychiatry
-  Inflammatory diseases



Strategic focus

1

During the last 5 years, Celon has delivered 6 successful data readouts, initiated 11 clinical trials, and raised capital through EU-found financings and public offerings.

2

Celon is led by a strong management team that brings to the organization a combined track record of managing national and global companies.

3

We aim to be resource- and capital-efficient in the development of our therapeutic candidates by selectively accessing complementary expertise and infrastructure through strategic partnerships.

4

We are building a leading innovative R&D and Clinical Development team that we believe has a unique perspective about how to identify high-potential product candidates and unlock their full value.


5

We are actively seeking opportunities to partner in terms of our clinical and preclinical programs by acquisition, in-licensing, or co-development.


Key strategic competences




Various pharmaceutical forms development




Intellectual property management



GMP Manufacturing - dry forms and dry powder inhalers




Global regulatory & supply chain




Full size commercial infrastructure in Poland and global network of partnerships outside Poland

Branded generic sales 2022



Improved sales dynamics in Poland in 2022



Sell-out data are sourced from the pharmacy market and include margins of the distributors. Sell-out data do not constitute a basis for recognition of the Company's revenues and should not be considered as statutory accounting data reported by the Company.

Generic business - incubation of technologies and capabilities and strong and growing source of cash flows

2020
8,5 mln USD

2021
19,5 mln USD*
*without profit sharing

2022
14,4 mln USD

